221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Phase 3

Terminated

• Conditions: Alzheimer's Disease
• Interventions: Drug: Aducanumab (BIIB037); Drug: Placebo

• Registration Number: NCT02477800
• Lead Sponsor: Biogen

Brief Summary

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) \[ADAS-Cog 13\], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) \[ADCS-ADL-MCI\].

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-06-18
• Study First Submitted QC: 2015-06-18
• Study First Posted: 2015-06-23
• Study Start: 2015-08-13
• Primary Completion: 2019-08-08
• Study Completion: 2019-08-08
• Disposition First Submitted: 2020-08-07
• Disposition First Submitted QC: 2020-08-07
• Disposition First Posted: 2020-08-14
• Results First Submitted: 2021-07-01
• Status Verified: 2021-08
• Results First Submitted QC: 2021-08-09
• Last Update Submitted: 2021-08-09
• Results First Posted: 2021-09-02
• Last Update Posted: 2021-09-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 1653

Inclusion Criteria

• Must meet all of the following clinical criteria for MCI due to AD or mild AD and must have:
• A Clinical Dementia Rating (CDR)-Global Score of 0.5.
• Objective evidence of cognitive impairment at screening
• An MMSE score between 24 and 30 (inclusive)
• Must have a positive amyloid Positron Emission Tomography (PET) scan
• Must consent to apolipoprotein E (ApoE) genotyping
• If using drugs to treat symptoms related to AD, doses must be stable for at least 8 weeks prior to screening visit 1
• Must have a reliable informant or caregiver

Key

Exclusion Criteria

• Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment
• Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year
• Clinically significant unstable psychiatric illness in past 6 months
• History of unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within 1 year prior to Screening
• Indication of impaired renal or liver function
• Have human immunodeficiency virus (HIV) infection
• Have a significant systematic illness or infection in past 30 days
• Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities
• Any contraindications to brain magnetic resonance imaging (MRI) or PET scans
• Alcohol or substance abuse in past 1 year
• Taking blood thinners (except for aspirin at a prophylactic dose or less)

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Low Dose	Aducanumab (BIIB037)	Monthly intravenous (IV) infusion
Low Dose	Placebo	Monthly intravenous (IV) infusion
High Dose	Aducanumab (BIIB037)	Monthly intravenous (IV) infusion
High Dose	Placebo	Monthly intravenous (IV) infusion

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 78	Baseline, Week 78	CDR-SB integrates assessments from 3 domains of cognition (memory, orientation, judgment/problem-solving) and 3 domains of function (community affairs, home/hobbies, personal care). Following caregiver interview and systematic patient examination, the rater assigns a score describing the participant's current performance level in each of these domains of life functioning. Prespecified severity anchors range from none = 0, questionable = 0.5, mild = 1, moderate = 2 to severe = 3 (the personal care domain omits the 0.5 score). "Sum of boxes" scoring methodology sums the score for each of the 6 domains and provides a value ranging from 0 to 18 that can change in increments of 0.5 or greater. Higher scores indicate greater disease severity. Mixed model for repeated measures (MMRM) analysis was used to analyze change from baseline in CDR-SB. A positive change from baseline indicates clinical decline.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (13 Items) (ADAS-Cog 13) Score at Week 78	Baseline, Week 78	ADAS-Cog13 comprises both cognitive tasks and clinical ratings of cognitive performance. The scale items capture word recall, ability to follow commands, the ability to correctly copy or draw an image, naming, the ability to interact with everyday objects, orientation, word recognition, memory, comprehension of spoken language, word-finding, and language ability, with a measure for delayed word recall and concentration/distractibility. The total score ranges from 0 to 85. An increase in score over time indicates increasing cognitive impairment. MMRM analysis was used to analyze change from baseline in ADAS-Cog 13. A positive change from baseline indicates clinical decline.
Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL-MCI) Score at Week 78	Baseline, Week 78	The ADCS-ADL-MCI consists of 17 instrumental items (e.g., shopping, preparing meals, using household appliances) and 1 basic item (getting dressed). Ratings reflect caregiver observations about the patient's actual functioning over the previous month and provide an assessment of change in the functional state of the participant over time. The total score ranges from 0 to 53, with lower values over time reflecting functional deterioration. MMRM analysis was used to analyze change from baseline in ADAS-ADL-MCI. A negative change from baseline indicates clinical decline.
Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 78	Baseline, Week 78	The MMSE is a widely used performance-based test of global cognitive status. It consists of 11 tasks that assess orientation, word recall, attention and calculation, language abilities, and visuospatial functions. The scores from the 11 tests are combined to obtain the total score, which ranges from 0 to 30, with lower scores over time indicating increasing cognitive impairment. MMRM analysis was used to analyze change from baseline in MMSE. A negative change from baseline indicates clinical decline.

Trial Locations

Locations (155)

St. Joseph's Hospital and Medical Center; 🇺🇸 Phoenix, Arizona, United States

Center for Neurosciences; 🇺🇸 Tucson, Arizona, United States

Neurology Center of North Orange County; 🇺🇸 Fullerton, California, United States

Senior Clinical Trials, Inc.; 🇺🇸 Laguna Hills, California, United States

Torrance Clinical Research Institute, Inc.; 🇺🇸 Lomita, California, United States

University of California - Los Angeles; 🇺🇸 Los Angeles, California, United States

UCSF - Memory and Aging Center; 🇺🇸 San Francisco, California, United States

California Neuroscience Research Medical Group Inc.; 🇺🇸 Sherman Oaks, California, United States

Southern California Research LLC; 🇺🇸 Simi Valley, California, United States

Institute for Neurodegenerative Disorders; 🇺🇸 New Haven, Connecticut, United States

Scroll for more (145 remaining)